ADVFN ADVFN

Hot Features

Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
Medexus Pharmaceuticals Inc

Medexus Pharmaceuticals Inc (MDP)

3,91
-0,05
(-1,26%)
Fermé 06 Juin 10:12PM

Medexus Pharmaceuticals Inc (MDP) Action

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Statistiques et détails clés

Dernier
3,91
( -1,26% )
Prix Achat
3,85
Prix Vente
3,92
Volume échangé
32 646
3,85 Fourchette du Jour 4,04
2,47 Plage de 52 semaines 4,17
Cap du marché
Clôture Veille
3,96
Ouverture
4,04
Dernière Transaction
200
@
3.91
Dernière heure de transaction
Volume financier
-
VWAP
-
Volume moyen (3 m)
$ 51 230
Actions en circulation
31 834 683
Rendement du Dividende (LTM)
Ratio Cours sur Bénéfices
-331,04
Bénéfice par action (BPA)
-0,01
Chiffre d'affairess (LTM)
99,43M
Bénéfice net (LTM)
-272k

À propos de Medexus Pharmaceuticals Inc

Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its primary products include IXINITY, an intravenous recombinant... Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its primary products include IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; GRAFAPEX, an injection to treat allogeneic hematopoietic stem cell transplantation in adult and pediatric patients, acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS); and Gleolan, an optical imaging agent for patients with glioma as an adjunct for the visualization of malignant tissue during surgery. The company’s products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, a ciprofloxacin and flucinolone acetonide; Trispan, a triamcinolone hexacetonide injectable suspension; and Trecondyv, a bifunctional alkylating agent for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation. In addition, it offers over the counter products comprising Nyda, a topical treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. was founded in 2000 and is based in Toronto, Canada. Show more

Secteur
Healthcare
Industrie
Pharmaceuticals
Site Web
Siège social
Toronto, Canada
Fondé
2026
Medexus Pharmaceuticals Inc est coté dans le secteur Healthcare de la Toronto Stock Exchange avec le ticker MDP. Le dernier cours de clôture d'Medexus Pharmaceuticals était de $3,96. Au cours de la dernière année, les actions de Medexus Pharmaceuticals ont été négociées dans une fourchette de prix de $ 2,47 à $ 4,17.

Medexus Pharmaceuticals compte actuellement 31 834 683 actions en circulation. La capitalisation boursière d'Medexus Pharmaceuticals est de $124,47 million. Medexus Pharmaceuticals a un ratio cours/bénéfice (ratio PE) de -331.04.

MDP Dernières nouvelles

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10.010.256410256413.94.053.79481203.93544479CS
40.010.256410256413.94.173.72427243.95275391CS
120.8728.61842105263.044.172.92531193.66989163CS
261.1843.22344322342.734.172.52488603.28345301CS
520.9933.9041095892.924.172.47463603.08598952CS
1562.68217.8861788621.235.551.12514532.74766345CS
260-3.47-47.01897018977.387.90.88442952.73141477CS

MDP - Frequently Asked Questions (FAQ)

What is the current Medexus Pharmaceuticals Inc share price?
The current share price of Medexus Pharmaceuticals Inc is $ 3,91
How many Medexus Pharmaceuticals Inc shares are in issue?
Medexus Pharmaceuticals Inc has 31 834 683 shares in issue
What is the market cap of Medexus Pharmaceuticals Inc?
The market capitalisation of Medexus Pharmaceuticals Inc is CAD 124,47M
What is the 1 year trading range for Medexus Pharmaceuticals Inc share price?
Medexus Pharmaceuticals Inc has traded in the range of $ 2,47 to $ 4,17 during the past year
What is the PE ratio of Medexus Pharmaceuticals Inc?
The price to earnings ratio of Medexus Pharmaceuticals Inc is -331,04
What is the cash to sales ratio of Medexus Pharmaceuticals Inc?
The cash to sales ratio of Medexus Pharmaceuticals Inc is 0,91
What is the registered address of Medexus Pharmaceuticals Inc?
The registered address for Medexus Pharmaceuticals Inc is 10 King Street East, Toronto, Ontario, M5C 1C3
What is the Medexus Pharmaceuticals Inc website address?
The website address for Medexus Pharmaceuticals Inc is www.medexus.com
Which industry sector does Medexus Pharmaceuticals Inc operate in?
Medexus Pharmaceuticals Inc operates in the Pharmaceuticals sector

MDP Transactions

Plus

Transactions différées

Pour obtenir des transactions en temps réel, améliorez votre compte

Passer à la version en temps réel
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock